Note: If you attended the live CE activity AND received CE credit (i.e. a pharmacist CE statement of credit with ACPE UAN 0221-9999-18-005-L01-P), you are NOT allowed to also receive credit for this home-study on-demand web activity.
|Co-produced by ProCE and the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education (CSPE)|
Several new coagulation factor concentrates to treat Hemophilia have been introduced over the past few years. Additionally, both Hemophilia A and B had FDA approved extended half-life factor products added to the list of treatment options making pharmacokinetic (PK) analysis even more important to avoid the risk of over or under treatment. Pharmacists and Nurses involved in the care of these patients need to be aware of the differences in PK parameters for each product and between patients. This education program will review the latest PK recommendations for Factor VIII and IX replacement and how to use and interpret PK parameters to assess treatment plans. Discussion on how these parameters might change throughout a patient’s life and other patient characteristics that may help predict the PK parameters will be evaluated. Available tools to assist with pharmacokinetic assessments will be discussed, with a focus on the value of population PK for hemophilia. Lastly, a team approach to the patient with counseling strategies will also be explored.
The target audience for this activity includes pharmacists and nurses working in hemophilia management, either in a hemophilia treatment center, specialty pharmacy, home infusion setting or health system. At the completion of this webinar, the participant will be able to:
- Identify and implement the latest recommendations for pharmacokinetic assessment for Factor VIII replacement, including extended half-life products, in patients with hemophilia A.
- Identify the PK parameters and clinical factors relevant to the optimal selection and dosing of FVIII replacement products and how to interpret PK data to individualize prophylaxis regimens in Hemophilia A patients.
- Explore population PK testing approaches as an alternative to traditional individual PK studies.
- Develop counseling strategies to achieve ideal PK dosing and monitoring in patients with hemophilia A.
Kerry Hansen, RN, BS
University of Minnesota Medical Center, Fairview
Hemophilia and Thrombosis Center
Jennifer Lissick, PharmD, BCPS
Children’s Minnesota Center for Bleeding and Clotting Disorders
Mark T. Reding, MD
Associate Professor of Medicine
Director, Center for Bleeding and Clotting Disorders
University of Minnesota Medical Center
Release Date: January 31, 2018
Expiration Date: January 31, 2021
This activity is jointly provided by ProCE, Inc. and the National Association of Specialty Pharmacy (NASP). ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-19-095-H01-P has been assigned to this home-study knowledge-based activity (initial release date January 31, 2018). This activity is approved for 1.0 contact hours (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
This CE activity is jointly provided by ProCE, Inc. and Wild Iris Medical Education, Inc. This activity provides 1.0 contact hours of nurse CE credit. Satisfy your pharmacology requirement with this webinar.
Wild Iris Medical Education, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed in this activity.Mr. Hansen is an Advisory Board member for Genentech. Dr. Lissick has no relevant commercial or financial relationships to disclose. Dr. Reding is an Advisory Board member for Bayer, Bioverativ, Genentech, Novo Nordisk, and Shire, and is a Speaker for Bioverativ and Shire. A portion of grant funds received by ProCE from Bayer HealthCare Pharmaceuticals, Inc. will be used to compensate the faculty for this presentation.
Please note: The information and views presented in this activity are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs and/or devices for unlabeled indications, which should be considered experimental. Participants are advised to consult manufacturer product information and the professional literature, and use professional judgment in applying the presented information in patient-care activities.
This CE activity is jointly provided by ProCE, Inc. and the National Association of Specialty Pharmacy (NASP), and supported by an educational grant from Bayer HealthCare Pharmaceuticals, Inc.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.